The FDA has approved a new drug application for Verkazia for the treatment of vernal keratoconjunctivitis in children and adults, according to a press release from Santen Pharmaceutical Co.
The application for Verkazia (cyclosporine ophthalmic emulsion 0.1%) was accepted by the FDA in October 2020. The approval was based on data from the pivotal VEKTIS study and the phase 2/3 NOVATIVE study that showed Verkazia demonstrated improvements in corneal inflammation and ocular itching, the release said.
“This is an important milestone in Santen’s aim to bring innovative solutions that